TEXAS HEART INSTITUTE JOURNAL, cilt.50, sa.1, ss.10-15, 2023 (SCI-Expanded)
Objective
Dual antiplatelet therapy has become standard in the first-line treatment of acute
coronary syndromes, but it increases the risk of bleeding complications. We aimed to
investigate pooled platelet concentrate's benefits in reducing postoperative bleeding in
patients undergoing off-pump coronary artery bypass surgery after a dual antiplatelet
drug loading dose.
Methods
One hundred nine patients who underwent emergent coronary artery bypass surgery
within the first 24 hours after being given dual antiplatelet therapy loading dose were
included in the study and divided into two groups; patients who were given pooled
platelet concentrate during the surgery (Group 1, n=63), and patients who were not
provided (Group 2, n=46). The amount of bleeding in the postoperative period and the
need for blood transfusions were recorded.
Results
The surgical drainage amounts were 475.39±101.94 ml in Group 1 and 679.34±232.03
ml in Group 2 (p=0.001). The need for surgical revisions was 0% and 15.2% in Group 1
and Group 2, respectively (p=0.002). The duration of hospitalization after surgery was
4 (4-6) days in Group 1 and 6 (4-9) days in Group 2 (p=0.001). Total transfusions per
patient werehigher in Group 2 than in Group 1 (1 (1-4) units and 3 (2-7) units,
respectively, p=0.001).
Conclusions
Using perioperative pooled platelet concentrate in patients with dual antiplatelet
therapy reduces postoperative bleeding, and the need for all kinds of blood products,
and shortens the hospital stay. As a result,